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Dioxins [polychlorinated dibenzo-p-dioxins
(PCDDs)] belong to a group of chemicals
identified as persistent organic pollutants
(POPs) because of their tendency to resist
degradation and persist in the environment.
There are 75 possible PCDD congeners, of
which 7 are most often found in the human
body. 2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) is the prototype dioxin congener
and is the most toxic dioxin. Dioxins are
“endocrine-disrupting” chemicals. They enter
the body through ingestion of contaminated
food; dioxins accumulate in body lipids of liv-
ing organisms and magnify as they move up
the food chain. Dioxins have a long half-life;
the half-life of TCDD is estimated to be
between 7 and 11 years. 
The incidence of disorders of the male
reproductive tract such as testicular cancer,
cryptorchidism, and hypospadias has increased
over the past decades. It has been hypothe-
sized that dioxins may be partially responsible
for this increase (Toppari et al. 1996).
However, evidence supporting this hypothe-
sis has come largely from animal studies; a
few human studies have provided limited
evidence. Hardell et al. (2003) reported that
levels of certain polychlorinated biphenyls
(PCBs) were higher in mothers of men with
testicular cancer compared with controls.
Some PCBs are dioxin-like and produce
responses similar to dioxins. Egeland et al.
(1994) found an inverse relation between
serum TCDD levels and serum testosterone
in chemical production workers. Men prena-
tally exposed to PCBs and polychlorinated
dibenzofurans (PCDF) in the Yucheng rice
oil poisoning had a higher percentage of
sperm with abnormal morphology, lower
sperm motility, and decreased capacity of
sperm to penetrate hamster oocytes (Guo
et al. 2000). Transplacentally exposed chil-
dren also had shorter penises at 11–14 years
of age (Guo et al. 1993). We have also
reported an inverse association between
serum dioxin levels and benign prostatic
hyperplasia (BPH) in a cross-sectional study
(Gupta et al. 2006). We found that men
with higher dioxin levels had lower odds of
having BPH. In the present study, a longitu-
dinal study of Vietnam War veterans, we
tested the hypothesis that higher TCDD
exposure leads to a lower risk of being diag-
nosed with BPH. We also studied the associ-
ation between TCDD exposure and serum
testosterone.
Materials and Methods
The Air Force Health Study is a prospective
study of Operation Ranch Hand veterans and a
comparison group of other Air Force veterans
designed to assess the effects of exposure to
Agent Orange and its TCDD contaminant
during the Vietnam War. Operation Ranch
Hand veterans were involved in spraying her-
bicides (including Agent Orange), and TCDD
was a contaminant in Agent Orange. The
comparison group was composed of other Air
Force veterans involved in aircraft missions
not involving herbicide spraying in Southeast
Asia in the same period (1962–1971) during
which the Ranch Hand group was active. The
comparison and Ranch Hand groups were
matched on age, race, and occupation in the
military. The study involved comprehensive
medical examinations conducted in 1982,
1985, 1987, 1992, 1997, and 2002, along
with regular review and coding of medical
records. Details of the study design and
methodology have been previously published
(Wolfe et al. 1990).
Serum TCDD levels were measured for
most veterans in 1987 at the Centers for
Disease Control and Prevention (Atlanta,
GA) using high-resolution gas chromatogra-
phy and high-resolution mass spectrometry;
TCDD levels were reported in parts per tril-
lion on a lipid weight basis (Patterson et al.
1987). For those veterans for whom TCDD
levels were measured after 1987 (n = 295),
the TCDD levels were extrapolated to 1987
using a ﬁrst-order kinetics model with a con-
stant half-life of 8.7 years (Michalek et al.
1996). Nondetectable TCDD levels were
replaced by the limit of detection divided by
√2. The TCDD exposure in the comparison
group is equivalent to the background expo-
sure in the general population. According to
the National Human Adipose Tissue Survey
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BACKGROUND: Operation Ranch Hand veterans were involved in spraying herbicides, including
Agent Orange, during the Vietnam War in 1962–1971; Agent Orange was contaminated with
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). It has been hypothesized that dioxins may be par-
tially responsible for an increase of male reproductive tract disorders such as testicular cancer, cryp-
torchidism, and hypospadias.
OBJECTIVES: In this study, our objective was to assess the effect of serum TCDD concentration on
the risk of development of benign prostatic hyperplasia (BPH) and on serum testosterone levels.
METHODS: This study was a longitudinal, prospective cohort study made up of U.S. Air Force vet-
erans involved in Operation Ranch Hand. Other Air Force veterans who did not spray herbicides
were included as comparisons. BPH was determined by medical record review and by medical
examinations conducted during the study. Data were available for 971 Ranch Hand and
1,266 comparison veterans. We investigated the relationship between BPH and serum TCDD level
using the Cox proportional hazards models adjusted for testosterone levels, body mass index (BMI),
and the percentage change in BMI per year. 
RESULTS: In univariate and multivariate analyses, the risk of BPH decreased with increasing serum
TCDD in the comparison group. The multivariate risk ratio for BPH in the comparison group was
0.84 (95% conﬁdence interval, 0.73–0.98). Excluding men with prostate cancer, inﬂammatory or
other prostatic diseases did not substantially alter the association. Serum testosterone levels were
inversely associated with serum TCDD levels in both Ranch Hand and comparison groups.
CONCLUSIONS: TCDD exposure at general population levels is associated with a decreasing risk of
BPH with higher exposure levels. TCDD exposure is also negatively associated with serum testos-
terone levels.
KEY WORDS: benign prostatic hyperplasia, BPH, dioxins, endocrine disruptors, persistent organic
pollutants, Ranch Hand, testosterone, TCDD, Vietnam veterans. Environ Health Perspect
114:1649–1654 (2006). doi:10.1289/ehp.8957 available via http://dx.doi.org/ [Online 20 July 2006](NHATS), the mean TCDD body burden
for U.S. men was 4.22 ppt compared with a
mean TCDD level of 4.6 ppt in the compari-
son group (Orban et al. 1994).
Prostatic conditions such as BPH, prostate
cancer, inflammatory prostatic diseases, and
other prostatic diseases were coded from medi-
cal records according to the International
Classiﬁcation of Diseases and Related Problems,
Ninth Revision [World Health Organization
(WHO) 1979]. The occurrence of BPH and
prostate cancer were determined by medical
record review, which included the records
from the veteran’s personal physician and the
medical examinations conducted as part of
the study. The date of onset was defined as
the date of ﬁrst diagnosis. Serum total testos-
terone was measured by radioimmunoassay in
serum collected in the morning after an
overnight fast. Medication use was elicited by
interview and verified by medical record
review.
We calculated the percentage change in
body mass index (BMI) per year as
[(BMI1987 – BMItour) ÷ (BMItour × years since
end of tour until 1987)] × 100, where
BMI1987 is the BMI measured in the 1987
examination cycle and BMItour is the BMI at
the end of the Southeast Asia tour.
Participants were included in the analysis
if the serum TCDD level was measured
(207 comparison veterans and 99 Ranch
Hand veterans were excluded); testosterone
level was measured in 1987 (166 comparison
veterans and 44 Ranch Hand veterans were
excluded); BMI at the end of the Southeast
Asia tour was available (3 comparison veter-
ans were excluded); BPH outcome informa-
tion was available (7 comparison veterans and
7 Ranch Hand veterans were excluded); and
if participants were not taking testosterone
medications (1 comparison veteran and
1 Ranch Hand veteran were excluded). The
analytical cohort comprised 1,266 compari-
son veterans and 971 Ranch Hand veterans
who were followed up to 6 August 2004, after
which the data were censored.
Statistical analysis. Serum TCDD and
testosterone levels were log-transformed
because they were not normally distributed.
Serum TCDD levels were also divided into
quartiles. We used the Cox proportional haz-
ards regression model to calculate the multi-
variate relative risk (RR) for the diagnosis of
BPH. Time to BPH diagnosis was the depen-
dent variable and was calculated as the time
from birth to the date of BPH diagnosis,
death, or 6 August 2004, whichever was ear-
lier. Covariates were serum TCDD and testos-
terone levels [natural log (ln)-transformed],
BMI at the 1987 examination, and the per-
centage change in BMI per year. 
We used multivariate linear regression
analysis to model the relationship between
serum testosterone and TCDD levels.
ln-Transformed serum testosterone level in
1987 was the dependent variable. The predic-
tor variables were serum TCDD level (ln-
transformed), age, BMI at the time of
testosterone measurement, and the percentage
change in BMI per year.
We conducted a sensitivity analysis to out-
come definition. The association between
serum TCDD levels and the risk of BPH was
studied by excluding the following from the
study population: a) men with history of
prostate cancer; b) men with a history of
prostate cancer, inﬂammatory prostatic diseases,
or other prostatic diseases; c) men who devel-
oped BPH before 1988 (serum TCDD was
measured for most veterans in 1987, and this
would allow assessment of exposure before
assessment of the disease status); d) men who
developed BPH before 1991 (to allow a mini-
mum of 3 years between exposure and outcome
assessment); e) men who developed BPH before
1994 (to allow a minimum of 6 years between
exposure and outcome assessment); and f) men
who had a history of prostate cancer, inﬂamma-
tory prostatic diseases, or other prostatic dis-
eases or who developed BPH before 1994. 
All signiﬁcance tests were two sided with a
significance level of α≤0.05. All statistical
analyses were performed using SAS, version
8.02 (SAS Institute Inc., Cary, NC).
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Table 1. Descriptive characteristics of comparison
(n = 1,259) and Ranch Hand (n = 964) veterans in
the Air Force Health Study.
Characteristic Comparison Ranch  Hand
Age (years)a 48.8 ± 0.2 48.9 ± 0.2
Age at end of tour (years) 30.0 ± 0.2 29.8 ± 0.2
TCDD (ppt) 4.57 ± 0.08 26.93 ± 1.47
ln(TCDD) 1.38 ± 0.02 2.63 ± 0.04
ln(testosterone)a 6.24 ± 0.01 6.26 ± 0.01
BMIa 27.7 ± 0.11 27.5 ± 0.13
Percentage change  0.60 ± 0.02 0.60 ± 0.02
in BMI per year
Race [n (%)]
Black 77 (6.1) 57 (5.9)
White 1,182 (93.9) 907 (94.1)
Values shown are mean ± SE except where noted.
aValues at the 1987 examination.
Table 3. RR (95% CI) of developing BPH with increasing serum TCDD levels among comparison and Ranch
Hand veterans in the Air Force Health Study.
Comparison Ranch Hand
Univariate RR  Multivariate RR Univariate RR Multivariate RR
Method (95% CI) (95% CI) (95% CI) (95% CI)
By continuous variable
ln(TCDD) 0.78 (0.68–0.89) 0.84 (0.73–0.98) 1.07 (0.98–1.16) 1.12 (1.03–1.22)
ln(testosterone)a 1.55 (1.21–2.00) 1.41 (1.07–1.84) 1.59 (1.19–2.11) 1.47 (1.08–2.00)
BMI 0.98 (0.96–1.00) 0.98 (0.95–1.00) 0.98 (0.96–1.01) 0.95 (0.93–0.98)
Percentage change 1.07 (0.95–1.20) 1.22 (1.05–1.41) 1.10 (0.96–1.26) 1.33 (1.12–1.57)
in BMI per year
By quartile
TCDD quartiles
I 1* 1** 0.84 (0.67–1.06)# 0.85 (0.68–1.07)##
II 0.91 (0.74–1.13) 0.96 (0.78–1.20) 0.83 (0.67–1.04) 0.91 (0.73–1.13)
III 0.75 (0.61–0.93) 0.81 (0.65–1.01) 0.79 (0.63–0.99) 0.91 (0.72–1.15)
IV 0.67 (0.54–0.83) 0.76 (0.61–0.95) 1.02 (0.81–1.28) 1.13 (0.89–1.44)
ln(testosterone)a 1.55 (1.21–2.00) 1.40 (1.07–1.84) 1.59 (1.12–2.11) 1.29 (0.99–1.68)
BMI 0.98 (0.96–1.00) 0.98 (0.95–1.00) 0.98 (0.96–1.00) 0.96 (0.93–0.98)
Percentage change  1.07 (0.95–1.20) 1.20 (1.03–1.39) 1.10 (0.96–1.26) 1.33 (1.14–1.54)
in BMI per year
Analyses were performed by treating ln(TCDD) as a continuous variable and also by dividing TCDD into quartiles. TCDD
quartile I of the comparison veterans is the referent group for other TCDD quartiles in both comparison and Ranch Hand
veterans.
aValues at the 1987 examination. *p < 0.001, **p = 0.049, #p = 0.12, and ##p = 0.18 for trend across TCDD categories.
Table 2. Distribution of the study population into quartiles based on serum TCDD levels.
Group/ TCDD Testosterone
TCDD quartile Range (ppt) Mean TCDD (ppt) NBPH/Ntot [mean ± SD (ng/mL)]
Comparison
I 0.42–2.97 2.14 167/319 606 ± 191
II 2.98–4.08 3.54 177/309 534 ± 153
III 4.09–5.53 4.74 172/315 517 ± 152
IV 5.54–54.8 7.87 189/316 491 ± 142
Total 705/1,259 537 ± 166
Ranch hand
I 0.57–6.50 4.14 137/240 583 ± 157
II 6.51–11.97 8.95 158/247 527 ± 167
III 11.98–26.69 18.40 131/235 542 ± 171
IV 26.70–617.75 76.16 125/242 530 ± 154
Total 551/964 545 ± 164
Abbreviations: NBPH, number of men with BPH in each quartile; Ntot, total number of men in the quartile.Results
Serum TCDD levels were higher in the Ranch
Hand group (mean ± SD, 26.9 ± 45.5 ppt;
median, 11.7 ppt; range, 0.6–617.8 ppt) than
in the comparison group (mean ± SD,
4.6 ± 2.9 ppt; median, 4.1 ppt; range:
0.4–54.8 ppt). Descriptive characteristics of
the comparison and Ranch Hand groups are
presented in Table 1. The two groups were
similar with respect to age, racial composition,
serum testosterone levels, BMI, and the per-
centage change in BMI per year. The compari-
son and Ranch Hand veterans were divided
into four quartiles based on serum TCDD lev-
els (Table 2). At the time of censoring, 56%
(705/1,259) of the comparison veterans and
57% (551/964) of the Ranch Hand veterans
had been diagnosed with BPH.
We evaluated the risk of BPH in relation
to the serum TCDD levels using the ln-trans-
formation of TCDD levels as the predictor
variable (Table 3). In univariate and multi-
variate analysis, the risk of BPH decreased with
increasing serum TCDD levels in the compari-
son group, but appeared to increase in the
Ranch Hand group. The multivariate RR for
BPH in the comparison group was 0.84 [95%
confidence interval (CI), 0.73–0.98]. This
implies that the risk of being diagnosed with
BPH decreases by 16% with exponential
(2.72-fold) increase in serum TCDD levels.
We performed further analyses using
serum TCDD quartiles (Table 3). The first
quartile of the comparison veterans was used
as the referent category for both the compari-
son and the Ranch Hand veterans. This was
done in order to compare the results of the
Ranch Hand veterans with those of the com-
parison veterans. In the comparison veterans
the risk of being diagnosed with BPH
decreased almost linearly with increasing
TCDD exposure quartiles (test for trend
= 0.049) (Table 3, Figure 1). In the Ranch
Hand veterans, the highest TCDD quartile
showed an increased risk of developing BPH
compared with the first quartile of the com-
parison veterans, which was not statistically
signiﬁcant (Table 3). The data were also ana-
lyzed using the first quartile of the Ranch
Hand veterans as the referent category for the
other three quartiles of the Ranch Hand veter-
ans. The relative risk of BPH was 1.07
(95% CI, 0.85–1.36; p = 0.55), 1.08 (95% CI,
0.85– 1.39; p = 0.53), and 1.35 (95% CI,
1.05–1.74; p = 0.02) for the second, third, and
fourth quartiles, respectively. We noted a trend
(p = 0.11) toward increased risk of BPH that
was conﬁned completely to the fourth quartile.
The first three quartiles had similar risks of
BPH diagnosis.
Results of the sensitivity analysis are pre-
sented in Tables 4 and 5. Among the compari-
son veterans the risk of BPH diagnosis
consistently decreased with increasing serum
TCDD levels on both continuous and categor-
ical analysis (Table 4). Among the Ranch
Hand veterans the risk of BPH diagnosis
appeared to increase with increasing TCDD
levels when TCDD was used as a continuous
variable (Table 5). On categorical analyses with
the ﬁrst quartile of the comparison veterans as
the referent category, the increased risk of BPH
diagnosis was conﬁned completely to the high-
est TCDD quartile among the Ranch Hand
veterans. The ﬁrst three quartiles of the Ranch
Hand veterans had a decreased risk (not statis-
tically significant) of being diagnosed with
BPH compared with the referent category
(Table 5, Figure 1).
We also examined the relationship between
serum TCDD levels and serum testosterone
levels. In multivariate linear regression analysis
(Table 6), serum testosterone was negatively
associated with serum dioxin levels in both the
comparison and the Ranch Hand veterans.
Further analyses were performed using the
TCDD quartiles, with the ﬁrst quartile of the
comparison veterans serving as the referent cate-
gory. A consistent decrease in serum testos-
terone was seen across all TCDD quartiles for
TCDD exposure, serum testosterone, and risk of BPH
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Figure 1. RR (95% CI) of developing BPH with
increasing serum TCDD levels among comparison
and Ranch Hand veterans in the Air Force Health
Study. TCDD quartile I of the comparison veterans
is the referent group for the Ranch Hand veterans.
Table 4. RR (95% CI) of developing BPH with increasing serum TCDD categories among comparison veterans in the Air Force Health Study.
BPH cases (n)/total RRa RRa (95% CI) by quartile p-Value 
Excluded subjects (n) (95% CI) p-Value I II III IV for trend
Men with history of prostate cancer 650/1,186 0.84 (0.73–0.98) 0.02 1 0.94 (0.75–1.18) 0.78 (0.62–0.98) 0.76 (0.61–0.96) 0.05
Men with history of prostate cancer, inﬂammatory 556/1,047 0.84 (0.71–0.99) 0.03 1 0.96 (0.76–1.22) 0.80 (0.62–1.02) 0.79 (0.61–1.02) 0.14
prostatic diseases, or other prostatic diseases
Men diagnosed with BPH prior to 1988 544/1,097 0.84 (0.71–0.99) 0.03 1 0.95 (0.74–1.21) 0.79 (0.61–1.01) 0.74 (0.57–0.96) 0.06
Men diagnosed with BPH prior to 1991 526/1,037 0.85 (0.72–1.01) 0.06 1 0.98 (0.76–1.25) 0.80 (0.62–1.03) 0.77 (0.59–1.00) 0.09
Men diagnosed with BPH prior to 1994 381/879 0.77 (0.64–0.94) 0.01 1 0.97 (0.73–1.28) 0.70 (0.52–0.94) 0.66 (0.49–0.90) 0.01
Men diagnosed with BPH prior to 1994 and men  330/767 0.75 (0.61–0.93) 0.01 1 0.98 (0.73–1.33) 0.69 (0.50–0.95) 0.68 (0.49–0.94) 0.02
with history of prostate cancer, inﬂammatory 
prostatic diseases, or other prostatic diseases
aAdjusted for testosterone levels in 1987, BMI in 1987, and the percentage change in BMI per year since the end of the Southeast Asia tour.
Table 5. RR (95% CI) of developing BPH with increasing serum TCDD categories among Ranch Hand veterans in the Air Force Health Study.
BPH cases (n)/total RRa RRa,b (95% CI) by quartile p-Value 
Excluded subjects (n) (95% CI) p-Value I II III IV for trend
Men with history of prostate cancer 512/907 1.11 (1.02–1.21) 0.02 0.86 (0.68–1.09) 0.95 (0.76–1.19) 0.89 (0.70–1.14) 1.14 (0.89–1.45) 0.23
Men with history of prostate cancer, inﬂammatory 448/819 1.11 (1.02–1.21) 0.02 0.92 (0.72–1.18) 0.98 (0.76–1.25) 0.93 (0.71–1.22) 1.22 (0.94–1.59) 0.23
prostatic diseases, or other prostatic diseases
Men diagnosed with BPH prior to 1988 403/816 1.18 (1.07–1.30) 0.001 0.81 (0.62–1.05) 0.79 (0.61–1.02) 0.82 (0.62–1.08) 1.20 (0.92–1.57) 0.01
Men diagnosed with BPH prior to 1991 394/785 1.19 (1.07–1.31) 0.001 0.82 (0.63–1.07) 0.80 (0.62–1.05) 0.85 (0.64–1.12) 1.24 (0.94–1.63) 0.01
Men diagnosed with BPH prior to 1994 272/657 1.19 (1.05–1.33) 0.005 0.74 (0.54–1.01) 0.78 (0.58–1.06) 0.73 (0.52–1.03) 1.16 (0.84–1.59) 0.02
Men diagnosed with BPH prior to 1994 and men 242/585 1.14 (1.01–1.29) 0.04 0.81 (0.58–1.12) 0.90 (0.65–1.25) 0.77 (0.53–1.12) 1.17 (0.84–1.64) 0.16
with history of prostate cancer, inﬂammatory 
prostatic diseases, or other prostatic diseases
aAdjusted for testosterone levels in 1987, BMI in 1987, and the percentage change in BMI per year since the end of the Southeast Asia tour. bTCDD quartile 1 of the comparison veterans was
the referent group.both Ranch Hand and comparison veterans
(Table 7, Figure 2).
Discussion
In this prospective cohort study, higher serum
TCDD levels in the comparison group are
associated with decreased risk of being diag-
nosed with BPH. Serum TCDD is also asso-
ciated with lower testosterone levels in both
Ranch Hand and comparison veterans.
The TCDD exposure levels in the com-
parison group are similar to the ‘background’
exposure levels in the general population
(4.22 ppt according to the 1987 NHATS)
(Orban et al. 1994). These results are consis-
tent with the results of our previous cross-
sectional study in which we found a decrease
in the odds of having BPH with increasing
TCDD body burden at general population
exposure levels (Gupta et al. 2006). To our
knowledge, the present study is the only
prospective study that has examined the asso-
ciation between serum TCDD and BPH.
In the present study we showed an inverse
association between serum testosterone and
TCDD levels. Other investigators have also
reported similar results (Egeland et al. 1994;
Johnson et al. 2001). Egeland et al. (1994)
studied 231 controls and 248 chemical pro-
duction workers who were occupationally
exposed to TCDD and found an inverse asso-
ciation between TCDD and serum testos-
terone. Johnson et al. (2001), in their study of
37 workers exposed to TCDD through spray-
ing of herbicides, found a statistically signiﬁ-
cant inverse relationship between TCDD and
testosterone in some of their analyses. The
present study has the largest sample size com-
pared to prior studies that have investigated
the same hypothesis.
The strengths of our study are that it was
prospective in nature and the loss to follow-up
was minimized. We included two groups: the
comparison veterans and the Ranch Hand vet-
erans. The comparison veterans were exposed
to the background exposure levels in the gen-
eral population, whereas the Ranch Hand
group was exposed to the background level
plus a varying amount of TCDD through
exposure to Agent Orange. This enables us to
study the effects of dioxin exposure in two
comparable populations with two different
mechanisms of exposure. The prospective
nature of this study resolves the temporal
ambiguity inherent in cross-sectional studies
because the serum dioxin levels were measured
before the veterans were diagnosed with BPH.
More than half of the participants—56% of
the comparison veterans and 57% of the
Ranch Hand veterans—had experienced the
outcome of interest (i.e., had been diagnosed
with BPH over the follow-up period). This
provides our study with adequate statistical
power to evaluate the relationship between
serum TCDD levels and BPH. The results of
the study were consistent when different exclu-
sion criteria were applied (Tables 4 and 5). 
Our study is limited by the fact that serum
levels were measured only for TCDD and we
did not have data on the levels of other dioxin
and dioxin-like congeners. TCDD was the
major dioxin in Agent Orange, and other
dioxin-like compounds were not considered in
the initial study design. In the general popula-
tion, TCDD accounts for < 5% of the total
dioxin toxic equivalents in the body (Schecter
and Gasiewicz 2003). The study population
was predominantly composed of whites; thus,
the results may not be generalized to the entire
population. BPH was determined by use of
medical records, which may result in some
misclassiﬁcation. However, any misclassiﬁca-
tion is unlikely to be differential with respect
to serum TCDD levels and thus is expected to
bias the study results toward the null. 
BPH was assessed as a dichotomous out-
come in this study. Correlating a continuous
outcome measure such as prostate volume with
TCDD levels is expected to be a more sensitive
measure of the effect of dioxins on prostate
growth. Although prostate volume measure-
ment is invasive, it merits consideration for
further studies. The data we used for assessing
the relationship between testosterone and
TCDD is cross-sectional in nature because
both TCDD and testosterone were measured
in 1987. Thus, the results represent associa-
tions and do not prove causation.
Prostatic growth in rats is sensitive to
TCDD exposure (Appendix). The mecha-
nisms of the effect of TCDD exposure on rat
prostate might help in explaining the observed
association between TCDD exposure and
BPH (Appendix).
TCDD is also known to decrease testos-
terone levels in adult male rats. In adult rats
exposed to TCDD, testosterone decreased in a
dose-dependent fashion, and there was a dose-
dependent decrease in volume per testis of
Leydig cell cytoplasm, nuclei, or total Leydig
cell volume (Johnson et al. 1992). TCDD
exposure also decreased the number of Leydig
cells, size of individual Leydig cells and the
volume per testis of smooth endoplasmic
reticulum and mitochondria (Johnson et al.
1994). Moreover, TCDD also inhibits the
compensatory rise in the concentration of
luteinizing hormone in plasma in response to
low testosterone levels in rats (Bookstaff et al.
1990a, 1990b).
The difference in the results for the com-
parison and the Ranch Hand groups with
respect to the association between serum
TCDD levels and the risk of being diagnosed
with BPH is surprising and not readily
explainable. The results for the quartiles I–III
of the Ranch Hand veterans were consistent
with the results of the comparison group
(Figure 1). However, the quartile IV showed
an increased risk that was not statistically sig-
nificant when compared with the referent
Gupta et al.
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Table 6. Association of serum testosterone (ln-transformed) with serum TCDD levels after controlling for
age, BMI, and the percentage change in BMI per year among comparison (n = 1,259) and Ranch Hand
(n = 964) veterans in the Air Force Health Study.
Comparison Ranch Hand
[coefﬁcient (95% CI)] [coefﬁcient (95% CI)]
ln(TCDD) –0.05 (–0.08 to –0.03) –0.02 (–0.04 to –0.002)
Agea –0.01 (–0.01 to –0.01) –0.01 (–0.01 to –0.01)
BMIa –0.02 (–0.03 to –0.02) –0.02 (–0.03 to –0.02)
Percentage change in BMI per year –0.040 (–0.069 to –0.010) –0.024 (–0.058 to 0.011)
aValues at the 1987 examination.
Table 7. Association of serum testosterone (ln-
transformed) levels (measure in 1987) with quartiles
of serum TCDD levels after controlling for age, BMI,
and the percentage change in BMI per year among
comparison and Ranch Hand veterans in the Air
Force Health Study.
TCDD quartiles Coefﬁcient (95% CI) p-Value
Comparison
I0 a (—) —
II –0.063 (–0.105 to –0.012) 0.004
III –0.048 (–0.091 to –0.005) 0.03
IV –0.079 (–0.123 to –0.036) < 0.001
Ranch hand
I 0.002 (–0.044 to 0.047) 0.94
II –0.052 (–0.098 to –0.007) 0.03
III –0.029 (–0.075 to 0.017) 0.22
IV –0.056 (–0.102 to –0.10) 0.02
aTCDD quartile I of the comparison veterans is the referent
group for other TCDD quartiles for both comparison and
Ranch Hand veterans. 
Figure 2. Association of ln-transformed serum
testosterone levels (measured in 1987) with quar-
tiles of serum TCDD levels after controlling for age,
BMI, and the percentage change in BMI per year
among comparison and Ranch Hand veterans in
the Air Force Health Study. TCDD quartile I of the
comparison veterans is the referent group for the
Ranch Hand veterans. The y-axis is the linear
regression coefﬁcient for the TCDD quartiles; error
bars indicate 95% CI.
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category, but it was statistically significant if
the comparison veterans were not used as the
referent group and TCDD was treated as a
continuous variable (Table 3). Also, there was
a statistically signiﬁcant trend toward higher
risk of BPH with increasing TCDD levels
when certain exclusion criteria were applied
(Table 5). This increased risk was confined
exclusively to the TCDD quartile IV. The
reason for this finding is not known. The
ﬁnding may have occurred due to chance, but
a few alternate explanations are also plausible.
First, the results are almost U-shaped, with
a decrease in risk followed by an increasing risk
on BPH. Other investigators studying
endocrine-active chemicals have also noticed
such results whereby the initial increase or
decrease was followed by a subsequent reversal.
For example, Eskenazi et al. (2005) studied the
risk of early menopause with exposure to
TCDD and found a nonmonotonic dose-
related association. They divided the data into
quintiles based on serum TCDD levels. The
risk ratio for the second, third, and fourth
quintiles compared with the ﬁrst quintile was
1.1, 1.4, and 1.6, respectively (test for trend,
p = 0.04); but for the fifth quintile the risk
ratio was 1.1. Similarly, in another study
(Markowski et al. 2001), a curvilinear associa-
tion between body weight and TCDD dose
was seen in both male and female Holtzman
rats; the body weight of rats exposed to lower
dioxin doses (20 ng/kg and 60 ng/kg) was
higher than in controls and rats exposed to a
higher TCDD dose (180 ng/kg). Hormones
and endocrine-disrupting chemicals are
thought to have a U- or inverted U-shaped
response because lower concentrations of a
hormone can stimulate a tissue, whereas higher
concentrations can have the opposite effect
(vom Saal et al. 1997). Mice exposed to lower
concentrations of estradiol or diethylstilbestrol
had higher prostate weights compared with
controls and mice exposed to higher concentra-
tions of estradiol and diethylstilbestrol
(vom Saal et al. 1997). Similarly, lower con-
centrations of bisphenol A (an estrogenic com-
pound) produced greater increases in body
weight and uterine weight than higher doses
(Rubin et al. 2001). Other studies have also
shown similar trends (vom Saal et al. 1995,
1998). Thus, it is possible that the effect of
TCDD exposure on the human prostate fol-
lows a U-shape, whereby the initial decrease in
BPH with lower doses is followed by increased
occurrence of BPH at higher doses.
Second, the mechanism of exposure to
TCDD differs between the comparison and
Ranch Hand veterans. The comparison group
was exposed to continuous background levels
of dioxins, whereas the Ranch Hand group was
exposed to a “bolus” of dioxins (specifically
TCDD) while involved in the spraying of
Agent Orange, in addition to exposure to
background levels of dioxins. A possible expla-
nation of the observed difference is that the
reproductive effects of dioxins may be most
pronounced when exposure occurs earlier in
life. Thus, the background exposure levels at
an early age may have a greater inﬂuence than
a bolus TCDD exposure later. We consider
the serum TCDD levels in the comparison
group representative of the exposure levels
experienced at a much younger age; however,
the TCDD levels in the Ranch Hand group
are sums of background exposure and bolus
exposure from TCDD-contaminated Agent
Orange. This bolus exposure may have
masked the effects of the earlier background
exposure and would make assessing the effects
of TCDD exposure difﬁcult. This difference
in the mechanism of TCDD exposure may
explain why the steady decrease in risk of BPH
observed in the comparison group is not seen
in the Ranch Hand veterans. Evidence from
prior studies shows that age at TCDD expo-
sure is an important determinant of the
effects. The median effective dose (ED50) of
TCDD that produces decreases in testosterone
and dihydrotestosterone levels in adult rats is
15 µg/kg TCDD (Moore et al. 1985), whereas
the ED50 for in utero and lactational TCDD
exposure of 0.16 µg/kg TCDD can produce a
spectrum of adverse effects such as decreased
weight of ventral prostate and seminal vesicles
and decreased epididymal sperm numbers
(Mably et al. 1992). Hardell et al. (2003)
reported that mothers of men with testicular
cancer had higher PCB levels than controls.
The men themselves did not have high PCB
levels. This suggests that TCDD exposure
during development is more predictive of
future outcomes. Further studies examining
age in relation to TCDD exposure and future
outcomes are needed.
Conclusions
TCDD exposure is associated with effects on
the human prostate. The risk of BPH
decreases with increasing TCDD exposure,
but may increase at higher doses. Also,
TCDD exposure is negatively associated with
serum testosterone levels.
Appendix
Biology of BPH Effect of TCDD on Rat Prostate
BPH may be caused by embryonic  TCDD inhibits prostate growth on 
reawakening of prostatic stromal cell  intrauterine exposure (Roman et al. 1995;
inductive potential (McNeal 1978). Theobald and Peterson 1997).
The number of epithelial and stromal cells  TCDD inhibits and delays differentiation 
increase in BPH. of prostatic luminal epithelial cells and 
pericordial smooth muscle cells (Roman 
et al. 1998; Theobald et al. 2000).
BPH nodules originate through ductal  TCDD decreases the number of buds, ductal
budding (McNeal 1978). tips, and main ducts and inhibits branching
morphogenesis of all prostate lobes (Roman 
et al. 1998; Timms et al. 2002) without 
impairing the AR signaling pathway 
(Ko et al. 2004).
Human prostate expresses androgen receptors TCDD decreases AR expression in the 
(ARs) throughout life (Barrack et al. 1983). ventral prostate (Ohsako et al. 2001;
Theobald et al. 2000).
Androgens are required for normal cell TCDD decreases androgen-responsive mRNA 
proliferation and differentiation. expression in the ventral prostate 
Development of BPH requires androgens (Roman and Peterson 1998).
during prostate development, puberty, 
and aging (McConnell 1995).
Nuclear AR levels may be higher in BPH TCDD decreases formation of androgen-
tissue than in normal tissue (Barrack et al.  responsive prostatic epithelial cells
1983). (Theobald et al. 2000).
The prostate completely fails to develop in These effects are not explained by decreased
testicular feminization syndrome in which testicular androgen production or by 
ARs are defective or completely absent. decreased conversion to dihydrotestosterone
(Roman et al. 1995; Timms et al. 2002).
CORRECTION
In the original manuscript published
online, “BMI at the start of the Southeast
Asia tour” was incorrect. It has been cor-
rected here (in the text and in Tables 1, 4,
and 5). “BMItour” is now defined as the
BMI at the end of the Southeast Asia tour.
Veterans were excluded from the study if
the BMI was not available for the end of
the Southeast Asia tour. REFERENCES
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